<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00379717</url>
  </required_header>
  <id_info>
    <org_study_id>VUB06-001</org_study_id>
    <secondary_id>TomoCT</secondary_id>
    <nct_id>NCT00379717</nct_id>
  </id_info>
  <brief_title>Concurrent Helical Tomotherapy With Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>Concurrent Helical Tomotherapy With Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC): a Phase I/II Trial of Radiation Dose Escalation and Fixed Dose Chemotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AZ-VUB</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AZ-VUB</source>
  <brief_summary>
    <textblock>
      This non-randomized Phase I/II study is designed to determine the maximum tolerated dose&#xD;
      (MTD) of thoracic radiotherapy and concurrent chemotherapy with cisplatin and docetaxel in&#xD;
      patients with LA-NSCLC. All patients will receive weekly administrations of docetaxel 20&#xD;
      mg/m² and cisplatin 20 mg/m2 concurrently with radiotherapy. Radiotherapy will be delivered&#xD;
      using helical tomotherapy in 30 daily fractions over six weeks. Patients should have&#xD;
      recovered fully from induction concurrent chemoradiotherapy before they continue with the&#xD;
      consolidation chemotherapy phase. Patients will be entered in cohorts of at least 5 subjects.&#xD;
&#xD;
      The first cohort of patients will receive 30 fractions of 2Gy in six weeks up to a total dose&#xD;
      of 60Gy. The concurrent chemotherapy starts at day 1 of the radiotherapy and will be&#xD;
      administered 2-4 hours before the radiotherapy.&#xD;
&#xD;
      The radiotherapy fraction size will be escalated to 2.36Gy in three steps.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dose escalation steps are:&#xD;
&#xD;
      30*2.00Gy = 60.0Gy (BED= 70.8Gy10 NID2= 60.0Gy) 30*2.12Gy = 63.6Gy (BED= 75.9Gy10 NID2=&#xD;
      64.2Gy) 30*2.24Gy = 67.2Gy (BED= 81.5Gy10 NID2= 68.5Gy) 30*2.36Gy = 70.8Gy (BED= 86.3Gy10&#xD;
      NID2= 72.9Gy) If MTD is not reached, protocol modification allowing further escalation can be&#xD;
      considered.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2006</start_date>
  <completion_date>April 2008</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the feasibility and toxicity of radiation dose escalation using helical tomotherapy concurrently with chemotherapy (docetaxel-cisplatin combination) in stage III locally advanced non small cell lung cancer (LA-NSCLC).</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To estimate efficacy parameters in terms of overall response rate, progression free survival and overall survival. To monitor quality of life (QOL) before, during and after treatment.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Non-Small-Cell Lung Carcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatinum</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tomotherapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Informed consent is required.&#xD;
&#xD;
          2. Histologically or cytologically confirmed NSCLC (adenocarcinoma, squamous cell&#xD;
             carcinoma, large cell carcinoma or a combination of these)&#xD;
&#xD;
          3. Patients must have a stage III unresectable LA-NSCLC:&#xD;
&#xD;
          4. Males or females aged between 18 and 75 years.&#xD;
&#xD;
          5. Life expectancy of at least 12 weeks.&#xD;
&#xD;
          6. ECOG performance status 0,1 or2.&#xD;
&#xD;
          7. Weight loss ≤ 10% within the last 3 months.&#xD;
&#xD;
          8. Laboratory requirements at entry:&#xD;
&#xD;
             • Blood cell counts: i. Absolute neutrophils ≥ 2.0 x 109/L ii. Platelets ≥ 100 x 109/L&#xD;
             iii. Haemoglobin ≥ 11 g/dl&#xD;
&#xD;
             • Renal function: i. Serum creatinine &lt; 1 x the upper limit of normal (UNL). ii. In&#xD;
             case of borderline value of serum creatinine, the 24h creatinine clearance should be &gt;&#xD;
             60 ml/min.&#xD;
&#xD;
             • Hepatic function: i. Serum bilirubin &lt; 1 x UNL ii. ASAT and ALAT &lt; 2.5 x UNL iii.&#xD;
             alkaline phosphatase &lt; 5 x UNL iv. Patient with ASAT and/or ALAT &gt; 1.5 x UNL&#xD;
             associated with alkaline phosphatase&gt; 2.5 x UNL is not eligible for the study.&#xD;
&#xD;
          9. Lung function tests at entry:&#xD;
&#xD;
               -  FEV1: ≥ 50 % x Normal value&#xD;
&#xD;
               -  DLCO: ≥ 50 % x Normal value&#xD;
&#xD;
         10. Adequate cardiac function.&#xD;
&#xD;
         11. Patient with either measurable and/or non-measurable lesion (according to RECIST&#xD;
             criteria, A1).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of small cell lung cancer.&#xD;
&#xD;
          2. Stage IIIB NSCLC, based on the presence of malignant pleural or pericardial effusion.&#xD;
&#xD;
          3. Pregnant or lactating women.&#xD;
&#xD;
          4. Patients (male or female) with reproductive potential not implementing adequate&#xD;
             contraceptive measures.&#xD;
&#xD;
          5. Prior systemic chemotherapy, immunotherapy, or biological therapy including&#xD;
             neoadjuvant or adjuvant treatment for NSCLC.&#xD;
&#xD;
          6. Prior surgery for NSCLC, if less than 5 years from study.&#xD;
&#xD;
          7. Prior radiotherapy for NSCLC.&#xD;
&#xD;
          8. History of prior malignancy, except for cured non-melanoma skin cancer, curatively&#xD;
             treated in-situ carcinoma of the cervix or other cancer curatively treated and with no&#xD;
             evidence of disease for at least five years.&#xD;
&#xD;
          9. Symptomatic peripheral neuropathy Grade ≥ 2 except if due to trauma.&#xD;
&#xD;
         10. Other serious concomitant illness or medical conditions:&#xD;
&#xD;
         11. Congestive heart failure or angina pectoris except if it is medically controlled.&#xD;
             Previous history of myocardial infarction within 1 year from study entry, uncontrolled&#xD;
             hypertension or arrhythmias.&#xD;
&#xD;
         12. History of significant neurological or psychiatric disorders including dementia or&#xD;
             seizures.&#xD;
&#xD;
         13. Active infection requiring IV antibiotics.&#xD;
&#xD;
         14. Active ulcer, unstable diabetes mellitus or other contra-indication to corticosteroid&#xD;
             therapy.&#xD;
&#xD;
         15. Superior vena cava syndrome contra-indicating hydration.&#xD;
&#xD;
         16. Pre-existing pericardial effusion.&#xD;
&#xD;
         17. Pre-existing symptomatic pleural effusion.&#xD;
&#xD;
         18. Significant gastrointestinal abnormalities, including requirement for intravenous&#xD;
             nutrition, active peptic ulcer disease, prior surgical procedures affecting&#xD;
             absorption.&#xD;
&#xD;
         19. Distant metastasis.&#xD;
&#xD;
         20. Concurrent treatment with any other experimental anti-cancer drugs.&#xD;
&#xD;
         21. Concomitant or within 4-week period administration of any other experimental drug&#xD;
             under investigation.&#xD;
&#xD;
         22. Significant ophthalmologic abnormalities.&#xD;
&#xD;
         23. Moderate to severe dermatitis.&#xD;
&#xD;
         24. Hypersensitivity to docetaxel, cisplatin, or any of its excipients.&#xD;
&#xD;
         25. Concomitant use of phenytoin, carbamazepin, barbiturates, or rifampicin.&#xD;
&#xD;
         26. Mental condition rendering the patient unable to understand the nature, scope, and&#xD;
             possible consequences of the study.&#xD;
&#xD;
         27. Patient unlikely to comply with protocol, i.e., uncooperative attitude, inability to&#xD;
             return for follow-up visits, and not likely to complete the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel Bral, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AZ-VUB</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samuel Bral, MD</last_name>
    <phone>003224776415</phone>
    <email>samuel.bral@uzbrussel.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicolas Fontaine, Mr</last_name>
    <phone>0032 2 477 54 61</phone>
    <email>nicolas.fontaine@uzbrussel.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Jette</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel Bral, MD</last_name>
      <phone>0032 2 477 64 15</phone>
      <email>samuel.bral@uzbrussel.be</email>
    </contact>
    <contact_backup>
      <last_name>Nicolas Fontaine, Mr</last_name>
      <phone>0032 2 477 54 61</phone>
      <email>nicolas.fontaine@uzbrussel.be</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2006</verification_date>
  <study_first_submitted>September 21, 2006</study_first_submitted>
  <study_first_submitted_qc>September 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2006</study_first_posted>
  <last_update_submitted>March 12, 2008</last_update_submitted>
  <last_update_submitted_qc>March 12, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2008</last_update_posted>
  <responsible_party>
    <name_title>Bral Samuel</name_title>
    <organization>UZ Brussel</organization>
  </responsible_party>
  <keyword>helical tomotherapy</keyword>
  <keyword>dose escalation</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

